- Home
- JPC vs AGIO Comparison
JPC vs AGIO Comparison
Compare JPC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- AGIO
- Stock Information
- Founded
- JPC 2003
- AGIO 2007
- Country
- JPC United States
- AGIO United States
- Employees
- JPC N/A
- AGIO N/A
- Industry
- JPC Investment Managers
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- AGIO Health Care
- Exchange
- JPC Nasdaq
- AGIO Nasdaq
- Market Cap
- JPC 2.6B
- AGIO 2.3B
- IPO Year
- JPC N/A
- AGIO 2013
- Fundamental
- Price
- JPC $8.27
- AGIO $36.78
- Analyst Decision
- JPC
- AGIO Buy
- Analyst Count
- JPC 0
- AGIO 6
- Target Price
- JPC N/A
- AGIO $57.00
- AVG Volume (30 Days)
- JPC 998.5K
- AGIO 779.8K
- Earning Date
- JPC 01-01-0001
- AGIO 10-30-2025
- Dividend Yield
- JPC 7.57%
- AGIO N/A
- EPS Growth
- JPC N/A
- AGIO N/A
- EPS
- JPC N/A
- AGIO 11.13
- Revenue
- JPC N/A
- AGIO $40,875,000.00
- Revenue This Year
- JPC N/A
- AGIO $28.19
- Revenue Next Year
- JPC N/A
- AGIO $152.14
- P/E Ratio
- JPC N/A
- AGIO $3.31
- Revenue Growth
- JPC N/A
- AGIO 30.57
- 52 Week Low
- JPC $5.94
- AGIO $23.42
- 52 Week High
- JPC $7.36
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- JPC 78.90
- AGIO 48.43
- Support Level
- JPC $8.05
- AGIO $34.97
- Resistance Level
- JPC $8.28
- AGIO $37.91
- Average True Range (ATR)
- JPC 0.03
- AGIO 1.67
- MACD
- JPC 0.02
- AGIO -0.21
- Stochastic Oscillator
- JPC 93.18
- AGIO 48.57
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.